Suppr超能文献

补充褪黑素可减轻铁过载地中海贫血患者的骨密度下降和循环氧化应激。

Melatonin Supplementation Alleviates Bone Mineral Density Decline and Circulating Oxidative Stress in Iron-Overloaded Thalassemia Patients.

作者信息

Piriyakhuntorn Pokpong, Tantiworawit Adisak, Phimphilai Mattabhorn, Kaewchur Tawika, Niprapan Piangrawee, Srivichit Bhumrapee, Apaijai Nattayaporn, Shinlapawittayatorn Krekwit, Chattipakorn Nipon, Chattipakorn Siriporn C

机构信息

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

出版信息

J Pineal Res. 2025 Apr;77(3):e70055. doi: 10.1111/jpi.70055.

Abstract

Thalassemia patients often exhibit low bone mineral density (BMD). The iron overload associated with thalassemia elevates oxidative stress levels, leading to reduced BMD. Melatonin improves BMD in postmenopausal osteopenia, however, its effect on BMD in thalassemia patients with iron overload has not been investigated. A randomized controlled study was conducted at Hematology Clinic, Faculty of Medicine, Chiang Mai University. Thalassemia patients with osteopenia and iron overloaded condition, as indicated by BMD Z-score <-2 at l-spine, femoral neck, or total hip, and serum ferritin level > 500 μg/L were recruited in this study. Patients were randomized to receive either melatonin 20 mg/day or placebo at bedtime for 12 months. BMD was re-evaluated 12 months after interventions. Bone turnover markers (BTM), malondialdehyde (MDA as an oxidative stress marker), and pain scores were assessed at baseline, 6, and 12 months. The outcomes, including BMD, BTM, MDA, and pain scores, were evaluated in all patients. Forty-one thalassemia patients (18 males) were enrolled in the study and randomly assigned to either the melatonin group (n = 21) or the placebo group (n = 20). Characteristics of patients were not differences between groups. Mean age was 30.8 ± 6.2 years old. Thirty-three patients (80.4%) were transfusion-dependent patients. At 12 months, mean BMD at l-spine in melatonin group was not significantly different from placebo group (p = 0.069). However, l-spine BMD at 12 months in the melatonin group was significantly greater than baseline (p = 0.029). Serum levels of P1NP and MDA were significantly reduced at 6 months compared to baseline following melatonin treatment. The melatonin group experienced a notable decrease in back pain scores after 12 months compared to the initial measurements. 20 mg daily melatonin supplementation for 12 months alleviated l-spine BMD loss in iron-overloaded thalassemia with low BMD. Melatonin also significantly reduced circulating oxidative stress and mitigated back pain in these patients.

摘要

地中海贫血患者常表现出低骨矿物质密度(BMD)。与地中海贫血相关的铁过载会提高氧化应激水平,导致骨矿物质密度降低。褪黑素可改善绝经后骨质减少患者的骨矿物质密度,然而,其对铁过载地中海贫血患者骨矿物质密度的影响尚未得到研究。在清迈大学医学院血液科进行了一项随机对照研究。本研究招募了骨量减少且铁过载的地中海贫血患者,其腰椎、股骨颈或全髋部的骨密度Z评分<-2,血清铁蛋白水平>500μg/L。患者被随机分为两组,一组在睡前服用20mg/天的褪黑素,另一组服用安慰剂,为期12个月。干预12个月后重新评估骨密度。在基线、6个月和12个月时评估骨转换标志物(BTM)、丙二醛(作为氧化应激标志物的MDA)和疼痛评分。对所有患者的骨密度、骨转换标志物、丙二醛和疼痛评分等结果进行评估。41例地中海贫血患者(18例男性)参与了本研究,并随机分为褪黑素组(n = 21)或安慰剂组(n = 20)。两组患者的特征无差异。平均年龄为30.8±6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验